A national hypertension treatment program in Germany and its estimated impact on costs, life expectancy, and cost-effectiveness.
Almost 15 million Germans may suffer from untreated hypertension. The purpose of this paper is to estimate the cost-effectiveness of a national hypertension treatment program compared to no program. A Markov decision model from the perspective of the statutory health insurance (SHI) was built. All data were taken from secondary sources. The target population consists of hypertensive male and female patients at high or low risk for cardiovascular events at different age groups (40-49, 50-59, and 60-69 years). The analysis shows fairly moderate cost-effectiveness ratios even for low-risk groups (less than 12,000 euros per life year gained). In women at high risk antihypertensive treatment even leads to savings. This suggests that a national hypertension treatment program provides good value for money. Given the considerable costs of the program itself, any savings from avoiding long-term consequences of hypertension are likely to be offset, however.
Gandjour
Afschin
A
Institute of Health Economics and Clinical Epidemiology, University of Cologne, Cologne, Germany. afschin.gandjour@uk-koeln.de
Stock
Stephanie
S
D000368:Aged; D002318:Cardiovascular Diseases / Q000517:prevention & control; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D005260:Female; D005858:Germany; D017048:Health Care Costs; D006801:Humans; D006973:Hypertension / Q000191:economics / Q000628:therapy*; D008017:Life Expectancy; D008297:Male; D008390:Markov Chains; D008875:Middle Aged; D009313:National Health Programs / Q000191:economics*; D016730:Program Development; D015397:Program Evaluation; D012307:Risk Factors